OKYO Pharma Receives 'Positive Feedback' From FDA Meeting About Phase 3 Trial of Urcosimod to Treat Neuropathic Corneal Pain
OKYO Pharma (OKYO) said Wednesday it has received "positive feedback" from its US Food and Drug Administration Type D meeting concerning its lead drug candidate urcosimod to treat neuropathic corneal pain. The biopharmaceutical company said the FDA supported urcosimod's advancement into a global phase 3 pivotal trial, and that the regulator's feedback provides increased clarity around its regulatory strategy.
OKYO Pharma (OKYO) said Wednesday it has received "positive feedback" from its US Food and Drug Administration Type D meeting concerning its lead drug candidate urcosimod to treat neuropathic corneal pain.
The biopharmaceutical company said the FDA supported urcosimod's advancement into a global phase 3 pivotal trial, and that the regulator's feedback provides increased clarity around its regulatory strategy.